Nevada
Appellate Courts
Appellate Case Management System
C-Track, the browser based CMS for Appellate Courts
Disclaimer: The information and documents available here should not be relied upon as an official record of action.
Only filed documents can be viewed. Some documents received in a case may not be available for viewing.
Some documents originating from a lower court, including records and appendices, may not be available for viewing.
For official records, please contact the Clerk of the Supreme Court of Nevada at (775) 684-1600.

Case Information: 85412
Short Caption:CITY OF RENO VS. TEVA PHARMACEUTICALS USA, INC.Court:Supreme Court
Related Case(s):81121
Lower Court Case(s):Washoe Co. - Second Judicial District - CV1801895Classification:Civil Appeal - General - Other
Disqualifications:ParraguirreCase Status:Remittitur Issued/Case Closed
Replacement:Justice Bell for Justice ParraguirrePanel Assigned: Panel
To SP/Judge:09/28/2022 / Wasick, DavidSP Status:Completed
Oral Argument:Oral Argument Location:
Submission Date:How Submitted:

+ Party Information

Docket Entries
DateTypeDescriptionPending?Document
09/27/2022Filing FeeFiling Fee Waived. State/County/Municipality. (SC)
09/27/2022Notice of Appeal DocumentsFiled Notice of Appeal. Appeal docketed in the Supreme Court this day. (Docketing Statement mailed to Counsel for Appellant) (SC)22-30377
09/27/2022Notice/OutgoingIssued Notice to Pay Supreme Court Filing Fee. No action will be taken on this matter until filing fee is paid. Due Date: 7 days. (NOTICE ISSUED INADVERTENTLY - NO FEE DUE FOR CITY OF RENO) (SC)
09/27/2022Notice/OutgoingIssued Notice of Referral to Settlement Program. This appeal may be assigned to the settlement program. Timelines for requesting transcripts and filing briefs are stayed. (SC)22-30388
09/28/2022Settlement NoticeIssued Notice: Assignment to Settlement Program. Issued Assignment Notice to NRAP 16 Settlement Program. Settlement Judge: David Wasick. (SC)22-30432
10/10/2022Settlement Program ReportFiled ECAR/Not Appropriate for Settlement Program. This case is not appropriate for mediation. (SC)22-31776
10/17/2022Docketing StatementFiled Appellant's Civil Docketing Statement. (REJECTED PER NOTICE FILED ON 10/18/22) (SC)
10/18/2022Settlement Order/ProceduralFiled Order Removing From Settlement Program/Briefing Reinstated. This appeal is removed from the settlement program. Appellant(s): 14 days transcript request; 90 days opening brief. (SC)22-32735
10/18/2022Notice/OutgoingIssued Notice of Rejection of Deficient Docketing Statement. Corrected docketing statement due: 5 days. (SC)22-32759
10/20/2022Docketing StatementFiled Appellant's Civil Docketing Statement. (SC)22-33080
10/21/2022OtherChief Justice Ron Parraguirre disqualified from participation in this matter. Disqualification Reason: Lawyers and Judges. (SC)
10/25/2022Transcript RequestFiled Request for Transcript of Proceedings. Transcripts requested: 8/2/22. To Court Reporter: Connie Eisenberg. (SC)22-33642
11/16/2022TranscriptFiled Notice from Court Reporter. Connie Eisenberg stating that the requested transcripts were delivered. Dates of transcripts: 8/2/22. (SC)22-36072
01/04/2023MotionFiled Stipulation To Request An Extension Of Time For Opening Brief. (SC).23-00177
01/09/2023Order/ProceduralFiled Order. The parties' have filed a stipulation for a 120-day extension of time to file the opening brief and appendix. The stipulation provides no cause to warrant that length of extension. Appellant shall have until February 16, 2023, to file and serve the opening brief and appendix. fn1[ Further, the stipulation is not signed by counsel of record for all parties. It does not appear that counsel for respondents Endo Health Solutions, Inc. and Endo Pharmaceuticals, Inc. signed the stipulation. ] (SC)23-00600
02/07/2023MotionFiled Appellant's Motion For Extension of Time. (SC)23-03828
02/17/2023Order/ProceduralFiled Order Granting Motion. Appellant shall have until April 17, 2023, to file and serve the opening brief and appendix. (SC)23-04918
04/15/2023BriefFiled Appellant's Opening Brief. (SC)23-11591
04/15/2023AppendixFiled Appellant's Appendix to Opening Brief. Vol. 1. (SC)23-11592
04/15/2023AppendixFiled Appellant's Appendix to Opening Brief. Vol. 2. (SC)23-11593
04/15/2023AppendixFiled Appellant's Appendix to Opening Brief. Vol. 3. (SC)23-11594
04/15/2023AppendixFiled Appellant's Appendix to Opening Brief. Vol. 4. (SC)23-11595
04/15/2023AppendixFiled Appellant's Appendix to Opening Brief. Vol. 5. (SC)23-11596
04/15/2023AppendixFiled Appellant's Appendix to Opening Brief. Vol. 6. (SC)23-11597
04/15/2023AppendixFiled Appellant's Appendix to Opening Brief. Vol. 7. (SC)23-11598
04/15/2023AppendixFiled Appellant's Appendix to Opening Brief. Vol. 8. (SC)23-11599
04/15/2023AppendixFiled Appellant's Appendix to Opening Brief. Vol. 9. (SC)23-11600
04/15/2023AppendixFiled Appellant's Appendix to Opening Brief. Vol. 10. (SC)23-11601
04/15/2023AppendixFiled Appellant's Appendix to Opening Brief. Vol. 11. (SC)23-11602
05/11/2023MotionFiled Respondents' (Allergan Finance and Allergan USA) Stipulation to Dismiss Appeal Against Allergan Finance, LLC F/K/A Actavis, Inc. F/K/A Watson Pharmaceuticals, Inc. and Allergan USA, Inc. Only, Pursuant to NRAP 42, and to Remove Allergan Finance, LLC. (SC)23-14976
05/15/2023MotionFiled Respondents' Stipulation to Request Extension of Time for Filing Respondents' Answering Brief. (SC)23-15234
05/15/2023Notice/OutgoingIssued Notice Motion/Stipulation Approved for Extension of Time to File the Answering Brief. (SC)23-15245
05/15/2023Order/ProceduralFiled Order Partially Dismissing Appeal. Pursuant to the stipulation of the parties, and cause appearing, this appeal is dismissed as to respondents Allergan Finance, LLC f/k/a Actavis, Inc. f/k/a Watson Pharmaceuticals, Inc.; and Allergan USA, Inc., only. NRAP 42(b). The clerk shall modify the caption accordingly. (SC)23-15261
06/05/2023BriefFiled Respondents' (Teva Pharmaceuticals USA, Inc. Cephalon, Inc., Actavis Pharma, Inc., Actavis LLC, and Watson Laboratories, Inc.) Answering Brief (REJECTED PER NOTICE FILED ON 6/6/2023). (SC)
06/05/2023AppendixFiled Respondents' (Teva Pharmaceuticals USA, Inc. Cephalon, Inc., Actavis Pharma, Inc., Actavis LLC, and Watson Laboratories, Inc.) Appendix to Answering Brief - Vol. 1. (SC)23-17674
06/05/2023AppendixFiled Respondents' Appendix to Answering Brief - Vol. 2. (SC)23-17675
06/05/2023AppendixFiled Respondents' Appendix to Answering Brief - Vol. 3. (SC)23-17676
06/05/2023AppendixFiled Respondents' Appendix to Answering Brief - Vol. 4. (SC)23-17677
06/05/2023AppendixFiled Respondents' Appendix to Answering Brief - Vol. 5. (SC)23-17678
06/06/2023Notice/OutgoingIssued Notice of Rejection of Deficient Brief. Corrected brief due: 5 days. (SC)23-17793
06/06/2023Notice/OutgoingIssued Notice to Provide Proof of Service. Due date: 7 days. (SC)23-17796
06/06/2023BriefFiled Respondents' (Teva Pharmaceuticals USA, Inc.,Cephalon, Inc., Actavis Pharma, Inc., Actavis LLC, and Watson Laboratories, Inc.) Answering Brief. (SC)23-17890
06/06/2023Notice/IncomingFiled Respondents' Proof of Service for the Answering Brief and Appendices - Vols. 1-5. (SC)23-17892
06/12/2023MotionFiled Appellant's Stipulation To Dismiss Appeal Against Teva Pharmaceuticals USA, Inc.; Cephalon, Inc.; Watson Laboratories, Inc.; Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.; And Actavis LLC, Only, Pursuant to NRAP 42, and to Remove Against Teva Pharmaceuticals USA, Inc.; Cephalon, Inc.; Watson Laboratories, Inc.; Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.; and Actavis LLC from the Caption of the Appeal. (SC)23-18532
06/13/2023Notice/OutgoingIssued Notice to Provide Proof of Service for Stipulation. Due date: 7 days. (SC)23-18641
06/14/2023Notice/IncomingFiled Respondents' (Endo Health Solutions, Inc. and Endo Pharmaceuticals, Inc.) Notice Of Suggestion Of Bankruptcy And Automatic Stay Of Proceedings. (SC)23-18793
06/14/2023Notice/OutgoingIssued Notice to Provide Proof of Service. Due date: 7 days. (SC)23-18817
06/14/2023Notice/IncomingFiled Respondents' Proof of Service Certificate of Service for the Notice of Suggestion of Bankruptcy and Automatic Stay of Proceedings. (SC)23-18910
06/20/2023Notice/IncomingFiled Appellant's (City of Reno) Proof of Service for Stipulation to Dismiss Appeal. (SC)23-19432
07/10/2023Order/DispositionalFiled Order Dismissing Appeal. Pursuant to the stipulation of the parties, this appeal is dismissed as to respondents Teva Pharmaceuticals USA, Inc.; Cephalon, Inc.; Watson Laboratories, Inc.; Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.; and Actavis LLC (collectively, the Teva Entities) only, with appellant and the Teva Entities each to bear their own costs and fees. NRAP 42(b). The clerk of this court shall modify the caption accordingly. The remaining respondents, Endo Health Solutions, Inc., and Endo Pharmaceuticals Inc. (Endo) have filed a notice informing this court that they have filed a petition for Chapter 11 bankruptcy and that this appeal is subject to the automatic stay. Given the applicability of the automatic stay, this appeal may linger indefinitely on this court's docket pending final resolution of the bankruptcy proceedings. Accordingly, this court concludes that judicial efficiency will be best served if the appeal is dismissed without prejudice. "This appeal is dismissed." LS/EC/LB. (SC)23-21831
08/04/2023RemittiturIssued Remittitur.(SC)23-25058
08/04/2023Case Status UpdateRemittitur Issued/Case Closed.(SC)
08/16/2023RemittiturFiled Remittitur. Received by District Court Clerk on 08/8/23. (SC)23-25058
Combined Case View